People

Thomas Möller is managing partner at BioMedPartners and chief investment officer at Kickfund, whose own biography explicitly confirms both affiliations. His background includes CFO responsibilities at NMT New Medical Technologies and senior work at PwC. He trained in economics at the University of Basel and is a Swiss certified public accountant. The manager’s current overview dates corporate founding to 2002, while his biography describes involvement from inception in 2003; these statements are retained with their differing corporate versus operational-history scope. These are institutional manager affiliations; no personal portfolio investment is inferred.

IAG publishes Carlo Brunetti as an external angel-network member. The member profile describes the following career and investing background, whose corporate positions are not independently asserted current: Notaio. Digital Deep Tech Life Science Notaio, appassionato di Life Science. Ha partecipato a libri su innovazione e finanziamento della stessa. Champion in società del settore biomedicale. Champion: Own IAG December18,2019 financing announcement names Carlo Brunetti as member and champion of the Sooma investment. This establishes deal-support responsibility within the member network; neither a personal cash amount nor individual subscription is inferred.

IAG publishes Giovanni Strocchi as an external angel-network member. The member profile describes the following career and investing background, whose corporate positions are not independently asserted current: Senior manager aziende digital. Digital Senior manager con esperienza internazionale in progetti di trasformazione digitale, Digital Media & AdTech, marketing, vendite, gestione di organizzazioni internazionali complesse, strategia, innovazione, programmi di trasformazione tecnologica ad ampio raggio, gestione di azionisti / consigli di amministrazione. Active angel Investor (2 Exit, 15 investimenti, Board member in tre) Champion:

Khaled Dridi is published by VU Venture Partners as Consumer Team Member (published investment affiliation). The current manager page places this named professional within its Consumer Team. This is a source-published investment-team affiliation, not proof of permanent employment, a statutory manager/director appointment or individual investment authority. The manager-linked professional profile and individually associated original portrait support the published identity, while a full career chronology and exact joining day are not supplied.

Safa Tlijani is published by VU Venture Partners as ClimateTech Team Member (published investment affiliation). The current manager page places this named professional within its ClimateTech Team. This is a source-published investment-team affiliation, not proof of permanent employment, a statutory manager/director appointment or individual investment authority. The manager-linked professional profile and individually associated original portrait support the published identity, while a full career chronology and exact joining day are not supplied.

Nada Bendhaw is published by VU Venture Partners as Healthcare Team Member (published investment affiliation). The current manager page places this named professional within its Healthcare Team. This is a source-published investment-team affiliation, not proof of permanent employment, a statutory manager/director appointment or individual investment authority. The manager-linked professional profile and individually associated original portrait support the published identity, while a full career chronology and exact joining day are not supplied.

Stephanie Monaghan O’Brien has been a member of the Morningside investment team since 1997. Her work includes operational guidance and financing for science and technology companies. Vigeo identifies her Harvard undergraduate and NYU law degrees; the Catholic Community Fund explicitly identifies her current investment-professional affiliation with Morningside Technology Advisory LLC. Existing Apellis role is preserved.

Gerald Chan co-founded Morningside with Ronnie Chan in 1986. He is publicly identified as Morningside chairman by its own digital-health summit team and as co-founder by Neutrolis and the American Academy of Arts and Sciences. He holds a doctorate in radiation biology from Harvard; his investing spans biotechnology, neuroscience and technology. Existing Apellis board affiliation is preserved.

Biotechnology executive and Schrödinger director, also listed as Rosana Kapeller. Co-founded ROME Therapeutics and previously served as founding chief scientific officer of Nimbus Therapeutics and research vice president at Aileron Therapeutics.

Dementia Discovery Fund venture partner and neuroscientist with prior research leadership experience at Rodin Therapeutics, Satori Pharmaceuticals and Pfizer.

Luca Giani is a senior principal at Alumni Ventures, working with Green D Ventures and The Yard Ventures. His earlier biotechnology entrepreneurship includes founding and leading Ilios Therapeutics, which develops preclinical approaches to neurodegenerative disease. He has also worked in technology commercialisation, healthcare investing, M&A at Credit Suisse and strategy consulting at Bain. He is a Termeer Fellow and previously held Harvard fellowships in life-science entrepreneurship and technology policy.

Lucy Edwardes-Jones is a TRIMTECH non-executive director and BGF life-sciences investor. She supports several drug-discovery and biotechnology companies at board level. Before BGF, she worked in strategy consulting with a healthcare and pharmaceutical focus. BGF early-stage life-sciences investor based in London and the South East. Earlier experience includes five years at CIL. Current TRIMTECH board affiliation and authentic issuer portrait are retained separately.

Alan Naylor is a published External Drug Discovery Adviser with the Parkinson’s Research Ventures programme. Own biography: Following a long career culminating as Vice President and Director of Medicinal Chemistry at GSK, Alan is now an independent drug discovery consultant. He is a co-inventor of Serevent (salmeterol), a marketed drug for use in asthma and chronic obstructive pulmonary disease (COPD). As a consultant, Alan has provided scientific and strategic advice to a range of academic and industrial clients and has been a member of several scientific advisory boards including membership of Wellcome Trust and Cancer Research UK committees. He is also a co-founder and adviser to Pathios Therapeutics Ltd., an Oxford-based start-up focused on immunooncology. The adviser/operating affiliation is distinct from a statutory directorship or personal cash check. Alan Naylor is advisor - united kingdom at Brandon Capital. His Brandon advisory affiliation dates to2015. His GSK medicinal-chemistry career includes drug-discovery leadership and co-invention of salmeterol; subsequent consulting and Pathios co-founding complement his existing Parkinson’s research and Lunac advisory roles. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.

Mervyn Turner, PhD, is a director of Amydis. He spent 27 years at Merck, including leadership of worldwide licensing and external research and service as its first Chief Strategy Officer, before retiring in 2011 and establishing MJ Turner Consulting. Mervyn Turner serves on Spinogenix’s board. He previously worked at Merck for 27 years, leading licensing and external research and serving as chief strategy officer before establishing an independent consultancy.

NMD Pharma nonexecutive director with neuroscience and rare-disease drug-development and venture-investing experience. The current issuer biography identifies her 2026 return to Roche Venture Fund as Head of Venture Investments, following Rewind and Pureos work. Holds a neuroscience/biochemistry doctorate from Freie Universität Berlin and an IE Madrid MBA. Roche’s current primary directory names Anja Harmeier as Head of Roche Venture Fund. NMD Pharma’s own biography states she returned as head in2026. The prior NMD and Mironid biography, original conference portrait and all company roles are preserved; no exact return date or personal check is inferred.

Draig Therapeutics founder and chief scientific officer, and Cardiff University Medicines Discovery Institute director. Specializes in AMPA receptor biology, medicinal chemistry and translational drug discovery.

Life-sciences investor and co-founder of Forbion, with experience in clinical development and biotechnology company governance.

Alex Mayweg is Versant Ventures’ current Managing Director. Joined2016 after Roche global chemistry leadership. Chemistry education spans Imperial College, Oxford doctorate and Stanford postdoctoral research.

Justin Klein is published by Vensana Capital as Co-founder and Managing Partner. Physician and lawyer with prior NEA medtech investing experience. Holds Duke undergraduate and medical degrees and a Harvard law degree. Existing NyraMedical board-observer identity is the same Vensana investor; the unrelated Health2047 engineering director is preserved separately. Justin Klein, MD, JD, serves on Cleerly’s board and co-founded Vensana Capital. He previously invested at NEA; he is distinct from Health2047’s engineer Justin Klein.

Amrinder Singh is published by Vensana Capital as Partner. Investor with earlier Medtronic Ventures, strategy and remote-monitoring experience, preceded by Thoratec engineering and product work. UC Davis engineering graduate with a Kellogg MBA; existing NyraMedical directorship preserved.

PfizerVentures primarypublished affiliation: Executive Director, WWBD / Partner. Marie-Claire Peakman, MRCPharm, PhD is a Partner at Pfizer Ventures and Executive Director, Worldwide Business Development. Marie-Claire is responsible for identifying, evaluating, making and managing equity investments aligned with the future directions of Pfizer. She currently has responsibility for Pfizer’s investments in Curve Therapeutics, DEM Biopharma, Greywolf Therapeutics, Mediar Therapeutics, Mission Therapeutics, Mozart Therapeutics, Normunity, and TRIMTECH Therapeutics. Her prior investment responsibilities include Vaccine Company Inc. (acquired by LLY) and observer roles with Capstan Therapeutics (acquired by ABBV), TRex Bio and Crossbow Therapeutics. She is also responsible for managing our investment in the Andera Partners’ BioDiscovery 7 Fund and is a member of the advisory board for the CT Bioscience Innovation Fund. Marie-Claire brings over 25 years of experience at Pfizer, leading platform technology groups that support small molecule programs from idea to development candidate selection across all therapeutic areas. These teams, including the Primary Pharmacology Group which she founded in 2009, played key roles in the identification of Paxlovid™ (nirmatrelvir), Cibinqo™ (abrocitinib), Litfulo™ (ritlecitinib) and multiple other small molecules currently in the clinic. Her experience extends to compound management, high throughput ADME, data support and management, genetically modified models, bioimaging and biobanking. Prior to Pfizer Marie-Claire gained experience at The Wellcome Foundation, at Guy’s Hospital, London, UK and held postdoctoral positions at Yale University. She has multiple roles on non-profit boards in the community. Marie-Claire received a B.Pharm.Hons. degree in Pharmacy and a Ph.D. in Physiology & Pharmacology from the University of Nottingham U.K. She is a Member of the Royal College of Pharmacy. Marie-Claire Peakman is a TRIMTECH non-executive director and Pfizer Ventures partner. Her Pfizer scientific leadership includes founding its Primary Pharmacology Group, followed by venture investment and portfolio oversight. She studied pharmacy and pharmacology at Nottingham and holds experience across discovery technologies and biotechnology boards.

Anja Leissner is published by byFounders as a member of its founder collective, described as founder based in Sweden. The collective provides experience and networks to portfolio companies; this is a network affiliation, not a manager employment title or a disclosed personal cash investment.